We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$4.59B
1-Year Est. Return
125.28%
This Fund
S&P 500
This Quarter
Est. Return
+30.69%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.45B
AUM Growth
+$454M
(+9.1%)
Cap. Flow
-$312M
Cap. Flow
% of AUM
-5.73%
Top 10 Holdings %
Top 10 Hldgs %
39.03%
Holding
130
New
20
Increased
22
Reduced
29
Closed
17
Top Buys
| 1 |
ArriVent BioPharma
AVBP
|
+$61.1M |
| 2 |
Cytokinetics
CYTK
|
+$52.8M |
| 3 |
Esperion Therapeutics
ESPR
|
+$33.3M |
| 4 |
Merck
MRK
|
+$32.2M |
| 5 |
Q32 Bio
QTTB
|
+$31M |
Top Sells
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
+$147M |
| 2 |
GRCL
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
|
+$93.5M |
| 3 |
United Therapeutics
UTHR
|
+$84.9M |
| 4 |
THRX
Theseus Pharmaceuticals, Inc. Common Stock
THRX
|
+$71.7M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
+$69.9M |
Sector Composition
| 1 | Healthcare | 99.34% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
51
Praxis Precision Medicines
PRAX
$8.84B
| $28.1M | 0.52% |
+460,512
| New | +$20.7M |
|
52
Heron Therapeutics
HRTX
$80M
| $28M | 0.51% |
10,111,550
+4,182,959
| +71% | +$10.5M |
|
|
SCPH
53
DELISTED
scPharmaceuticals
SCPH
| $27.9M | 0.51% |
5,559,528
| – | – |
|
|
SLRN
54
DELISTED
ACELYRIN
SLRN
| $27M | 0.5% |
4,001,711
| – | – |
|
55
Adicet Bio
ACET
$81M
| $26.9M | 0.49% |
715,446
+195,312
| +38% | +$8.08M |
|
56
Mineralys Therapeutics
MLYS
$2.39B
| $26.1M | 0.48% |
+2,021,424
| New | +$25M |
|
|
RNAM
57
DELISTED
Avidity Biosciences
RNAM
| $25.4M | 0.47% |
+994,100
| New | +$15.6M |
|
58
Xenon Pharmaceuticals
XENE
$6.53B
| $23.7M | 0.43% |
550,000
| – | – |
|
59
Regeneron Pharmaceuticals
REGN
$69.5B
| $21.9M | 0.4% |
22,800
+9,300
| +69% | +$8.84M |
|
|
KNTE
60
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $21.3M | 0.39% |
8,009,729
| – | – |
|
61
Arrowhead Research
ARWR
$10B
| $21.2M | 0.39% |
739,651
+420,000
| +131% | +$13.4M |
|
62
Neumora Therapeutics
NMRA
$304M
| $20.6M | 0.38% |
1,500,000
| – | – |
|
63
Dyne Therapeutics
DYN
$3.92B
| $20.1M | 0.37% |
+708,400
| New | +$16M |
|
|
MORF
64
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $19.7M | 0.36% |
558,500
+285,100
| +104% | +$9.56M |
|
65
DexCom
DXCM
$28.7B
| $19.5M | 0.36% |
140,300
+67,100
| +92% | +$8.43M |
|
66
AbCellera Biologics
ABCL
$2.05B
| $18.9M | 0.35% |
4,180,768
| – | – |
|
67
Immatics
IMTX
$1.3B
| $18.6M | 0.34% |
1,769,708
+226,301
| +15% | +$2.64M |
|
68
Verastem
VSTM
$489M
| $18M | 0.33% |
1,529,115
| – | – |
|
69
Amgen
AMGN
$193B
| $18M | 0.33% |
63,400
-63,900
| -50% | -$18.7M |
|
|
JBIO
70
Jade Biosciences
JBIO
$1.29B
| $16.7M | 0.31% |
16,154
-5,473
| -25% | -$4.18M |
|
71
TELA Bio
TELA
$36.7M
| $16.1M | 0.3% |
2,835,542
| – | – |
|
|
RPTX
72
DELISTED
Repare Therapeutics
RPTX
| $15.6M | 0.29% |
3,322,488
| – | – |
|
73
Passage Bio
PASG
$15.5M
| $13.7M | 0.25% |
506,229
| – | – |
|
74
Tyra Biosciences
TYRA
$1.9B
| $12.6M | 0.23% |
+768,638
| New | +$12.6M |
|
75
Corvus Pharmaceuticals
CRVS
$1.27B
| $12.4M | 0.23% |
6,943,654
| – | – |
|
Similar funds
CGI
LNWTC
SCM
AG
SCM
SV
ANTB
ECM